

ANALYSIS OFFERS OF MEDICINES GROUP N07CA02 ON THE MARKET OF UKRAINE

Teterich N.V., Kurylenko Yu. Ye
National University of Pharmacy, Ukraine
natalititi@ukr.net

According to the World Health Organization, migraine is a chronic neurological disease, the main manifestations of which are repeated attacks of severe headache, accompanied by nausea, vomiting, painful intolerance to bright light and loud sound. Migraine is classified as a disease that interferes with harmonious social adaptation of a person and has the following classification: G43.0 Migraine without aura; G43.1 Migraine with aura or classic migraine; G43.2 Migraine status; G43.3 Complicated migraine; G43.8 Other migraine; G43.9 Migraine, unspecified.

In accordance with the recommendations for the prevention of migraine, patients should take cinnarizine, which is a selective blocker of «slow» calcium channels, reduces the intake of calcium ions into the cells and decreases their concentration in the plasmalemma depot, reduces the tone of smooth muscles of arterioles, and enhances the vasodilating effect of carbon dioxide.

Accumulated clinical data show the efficacy of this calcium antagonist in about 48% of patients, which is in line with the results of treatment with drugs such as b-blockers and antidepressants.

The purpose of the study is to analyze the proposals on the pharmaceutical market of Ukraine for drugs of the N07CA02 group. Preparations for the elimination of dizziness / Cinnarizine.

The research used analytical and information generalization method.

As of 01.01.21 it was established that 5 cinnarizine preparations were registered without taking into account the release forms: Cinnarizine Sopharma, Stugeron, Cinnarizine, Cinnarizine Forte, Cinnarizine «OZ». Of these 3 domestic producers: Limited Liability Company «Experimental Plant» GNCLS», Private Joint Stock Company «Lekhim – Kharkiv», «Kyivmedpreparat», other foreign manufacturers – OJSC «Gideon Richter», Hungary, JSC «Sopharma», Bulgaria. That is, there are more offers from a domestic manufacturer, which is 60%:40%.

Form of release of cinnarizine - tablets of 25 mg and 75 mg. The average price range of cinnarizine tablets is from UAH 17.20 to UAH 57.68 per pack. The minimum cost of treatment varies in the range from UAH 27.00. up to UAH 115.10 for 1 month that is affordable for different categories of the population.

It should be noted that most of the drugs in this group are taken in combination and intermittently for prevention or symptomatic treatment. Since the triggers that affect the development of migraine and its types have not yet been fully studied.